MiR-195 suppresses non-small cell lung cancer by targeting CHEK1

Ben Liu; Jinli Qu; Fangxiu Xu; Yan Guo; Yu Wang; Herbert Yu; Biyun Qian

doi:10.18632/oncotarget.3255

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-195 suppresses non-small cell lung cancer by targeting CHEK1

Ben Liu, Jinli Qu, Fangxiu Xu, Yan Guo, Yu Wang, Herbert Yu and Biyun Qian _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:9445-9456. https://doi.org/10.18632/oncotarget.3255

Metrics: PDF 2662 views | HTML 3617 views | ?

Abstract

Ben Liu1,*, Jinli Qu1,*, Fangxiu Xu1, Yan Guo1, Yu Wang1, Herbert Yu2, Biyun Qian1,3

1Department of Epidemiology and Biostatistics, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

2Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA

3Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

*These authors have contributed equally to this work

Correspondence to:

Biyun Qian, e-mail: [email protected]

Keywords: non-small cell lung cancer, miR-195, CHEK1, prognosis, cell cycle

Received: December 08, 2014 Accepted: January 31, 2015 Published: March 25, 2015

ABSTRACT

MiR-195 suppresses tumor growth and is associated with better survival outcomes in several malignancies including non-small cell lung cancer (NSCLC). Our previous study showed high miR-195 plasma levels associated with favorable overall survival of non-smoking women with lung adenocarcinoma. To further elucidate role of miR-195 in NSCLC, we conducted in vitro experiment as well as clinical studies in a cohort of 299 NSCLC samples. We demonstrated that miR-195 expression was lower in tumor tissues and was associated with poor survival outcome. Overexpression of miR-195 suppressed tumor cell growth, migration and invasion. We discovered that CHEK1 was a direct target of miR-195, which decreased CHEK1 expression in lung cancer cells. High expression of CHEK1 in lung tumors was associated with poor overall survival. Our results suggest that miR-195 suppresses NSCLC and predicts lung cancer prognosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3255

Publication Alerts

Research Papers:

MiR-195 suppresses non-small cell lung cancer by targeting CHEK1

Abstract